GlassScriptPhysician profile
Virginia Mae Singer
NPI 1982724811
$1,874.98
in general payments reported to CMS, 2019-2025
9 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $488 · 2024: $366 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $429.31 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $371.61 | 2023-2025 | Abilify Mycite, Rexulti, Abilify Asimtufii |
| Gilead Sciences, INC. | $256.78 | 2025 | Vemlidy |
| Axsome Therapeutics, INC. | $247.04 | 2023-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $121.96 | 2025 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $121.81 | 2025 | Fasenra |
| Abbvie INC. | $118.69 | 2024 | |
| Bioxcel Therapeutics, INC. | $112.80 | 2023 | Igalmi |
| Janssen Pharmaceuticals, INC | $94.98 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.